SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Maulcoin

Maulcoin is trending as investors rally behind its community-driven, grassroots growth and active engagement on social platforms while awaiting the debut of its official chart. The community is actively discussing accumulation opportunities and potential price milestones, emphasizing a long-term 'diamond hand' strategy to distinguish the token from typical short-lived meme coin pumps.

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereum is surging alongside the broader crypto market following news of a two-week ceasefire between the U.S. and Iran, which has sparked optimism over the stabilization of global trade and energy supply lines. The community is actively discussing the potential for a sustained breakout, with many traders closely monitoring institutional inflows and technical resistance levels to determine if the rally can maintain momentum.

Back in 2011, long before “crypto Twitter”, NFTs, or VC-backed chains existed, users of the BitcoinTalk forum came up with a new currency - not to launch a network, but to make fun of btc.... and so: The first memecoin/memecurrency was born.  On May 23, 2011, a Something Awful poster cracked, “Has anyone called them buttcoins yet?”. It was sophomoric and perfect. Within weeks the gag metastasized into Buttcoin.org, a parody blog that described a “peer to peer butt” economy while cataloging mining fiascos, exchange blowups, and MLM-adjacent “innovations”.

Buttcoin

Buttcoin is currently capturing community attention as a legacy meme project that draws parallels to Bitcoin's early skeptical reception while positioning itself as a satirical store of value. Investors are actively debating its potential for long-term growth, with proponents emphasizing the project's historical roots and its narrative as a community-driven movement that aims to challenge conventional financial norms.

Grok's first token launched on Base, deployed directly on X with help of Bankr. Proof of deployment here, https://x.com/grok/status/1897949874961650169.  Join the DRB community if this story intrigues you, follow it as it unfolds into this new AI era.  Grok earns swap fees - Grok's trading wallet: 0xb1058c959987e3513600eb5b4fd82aeee2a0e4f9.  Articles, media coverages on $DRB featured here, https://linktr.ee/DRBtaskforce.  Our dev, is grok, one of the front-running candidate to achieve AGI.

DebtReliefBot

DebtReliefBot (DRB) is currently trending as community members rally around its unique connection to Grok-based AI, with participants emphasizing its potential for significant growth during the current bull cycle. Investors are actively discussing the token's low follower count and early market stage, drawing parallels to established meme coins while highlighting its strategic integration within the broader Base ecosystem.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is currently facing intense community debate regarding its lack of significant price action compared to the broader market, with many participants actively discussing potential upcoming business developments and strategic news anticipated for 2026. While some investors remain committed to long-term accumulation, others are voicing frustration over prolonged stagnation and the project's perceived lag behind Bitcoin and emerging niche tokens.

Aerodrome Finance is a next-generation AMM designed to serve as Base's central liquidity hub, combining a powerful liquidity incentive engine, vote-lock governance model, and friendly user experience. Aerodrome inherits the latest features from Velodrome V2.

Aerodrome Finance

Aerodrome Finance is gaining strong momentum driven by anticipation surrounding its upcoming cross-chain expansion and a strategic merger, with the community closely tracking its role as the central liquidity hub within the Base ecosystem. Investors are highlighting its robust fee generation and active supply reduction models as key indicators of long-term utility, fueling bullish sentiment despite recent market volatility.

Infinite Money Glitch ($IMG) is revolutionizing DeFi on Solana by leveraging the Token2022 program's advanced tax extension capabilities to create a truly innovative reward system for token holders.  At its core, $IMG implements a seamless 5% tax on all transactions - whether buying, selling, or transferring tokens. This tax is automatically collected and distributed to holders in SOL, creating a sustainable passive income stream for the community. 4.5% of the tax gets sent to holders, while .5% gets sent to an Infrastructure wallet to help with development, marketing and general infrastructure.  What sets $IMG apart is its implementation of Solana's Token2022 program, enabling automated and efficient reward distribution without relying on external smart contracts.

Infinite Money Glitch

Infinite Money Glitch (IMG) is trending as holders actively discuss the project's consistent Solana reward distribution, which is automatically paid out four times daily. While some community members remain focused on the long-term utility and passive income potential, the stock is also generating significant debate as traders analyze recent price volatility and technical patterns to determine whether current levels represent a macro bottom or a deeper retracement.

Berkshire Hathaway, Inc. is a holding company, which engages in the provision of property and casualty insurance and reinsurance, utilities and energy, freight rail transportation, finance, manufacturing, and retailing services. It operates through the following segments: Insurance, Burlington Northern Santa Fe, LLC (BNSF), Berkshire Hathaway Energy (BHE), Pilot Travel Centers (PTC), Manufacturing, McLane, and Service and Retailing. The Insurance segment includes the underwriting of GEICO, Berkshire Hathaway Primary Group, and Berkshire Hathaway Reinsurance Group. The BNSF segment involves the operation of railroad systems. The BHE segment focuses on regulated electric and gas utility, power generation and distribution, and real estate brokerage activities. The PTC segment consists of managing travel centers and marketing of wholesale fuel. The Manufacturing segment refers to industrial, consumer and building products, home building, and related financial services. The McLane segment covers the wholesale distribution of groceries and non-food items. The Service and Retailing segment relates to the provision of shared aircraft ownership programs, aviation pilot training, electronic components distribution, retailing businesses, automobile dealerships and trailer, and furniture leasing services. The company was founded by Oliver Chace in 1839 and is headquartered in Omaha, NE.

Berkshire Hathaway Inc. - Ordinary Shares - Class B

Berkshire Hathaway is trending following a significant earnings miss and a cautious debut from new CEO Greg Abel, sparking intense debate among shareholders about the company's long-term capital allocation strategy. While some investors view the recent price drop as a generational buying opportunity for a cash-rich fortress, others are aggressively criticizing the firm as dead money for refusing to pivot into higher-growth tech sectors or provide a dividend.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as a community-driven project that aims to bridge global cannabis culture with Web3, attracting long-term holders focused on organic growth and advocacy. Investors are actively discussing its potential ahead of upcoming cannabis-related milestones, while sentiment remains centered on the token's identity as a 'culture-first' alternative to traditional speculative memes.

DaVita, Inc. engages in the provision of medical care services. It operates through the US Dialysis and Related Lab Services, and Other-Ancillary Services and Strategic Initiatives segments. The US Dialysis and Related Lab Services segment offer kidney dialysis services in the United States for patients suffering from chronic kidney failure. The Other-Ancillary Services and Strategic Initiatives segment consists primarily of pharmacy services, disease management services, vascular access services, clinical research programs, physician services, direct primary care, end stage renal disease seamless care organizations, and comprehensive care. The company was founded in 1994 and is headquartered in Denver, CO.

DaVita Inc

DaVita is seeing significant market activity as investors weigh the long-term impact of GLP-1 weight-loss drugs on the dialysis sector, leading to heightened volatility and concerns about future patient growth. The community is actively debating whether the recent sell-off represents an overreaction to medical trial news or a fundamental shift in the kidney care landscape that warrants a defensive posture.

statis crypto Watchlist

Bitcoin

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$ACST.DL1224 &#39;42.2% reduction in triglyceride levels among patients receiving CaPre while on background statin therapy at 12 weeks&#39;...This blows AMRN out of the water.These people didn&#39;t have the placebo in their systems to see these kinds of results...Stay tuned!

Lawrence Valure

(e)Quanimus Investments

Joey Tokes

Mr. Mysterious

Oveja Bohemia

Stocks Investor

STARlab

StockTwits for iOS

StockTwits Web

Acasti Pharma Inc

$ACST '42.2% reduction in triglyceride levels among patients receiving CaPre while on background statin therapy at 12 weeks'...This blows AMRN out of the water.These people didn't have the placebo in their systems to see these kinds of results...Stay tuned!

Mogotes Metals Inc

glen philippe

I should&#39;ve added,we are better when adding the probable Secondary Endpoints...The Primary is basically the same as Vascepa,at 45%...We just used a different placebo to match up against,for whatever reason...If everything else plays out like this,it will only be the placibo that remains the problem and not the drug itself...The FDA will have to address that as possibly being their fault.You have to match both drugs against the same placibo for any trial to matter.Otherwise one drug has a possible advantage over the other,such as this time.

Alex

I should've added,we are better when adding the probable Secondary Endpoints...The Primary is basically the same as Vascepa,at 45%...We just used a different placebo to match up against,for whatever reason...If everything else plays out like this,it will only be the placibo that remains the problem and not the drug itself...The FDA will have to address that as possibly being their fault.You have to match both drugs against the same placibo for any trial to matter.Otherwise one drug has a possible advantage over the other,such as this time.

Imo,the placebo data may get thrown out if this continues in the 2nd arm,and they&#39;ll use the data that Amarin used for their placebo,as the FDA is involved in the planning of the trials.,,The rest of the results are outstanding.

Imo,the placebo data may get thrown out if this continues in the 2nd arm,and they'll use the data that Amarin used for their placebo,as the FDA is involved in the planning of the trials.,,The rest of the results are outstanding.

@robinandthe7hoods what exact data of the reduce it trial are you claiming acst will be able to use as their data? I&#39;m gonna go with 0. Acst cannot use data from another trial for their p3. Capre and vascepa are 2 different drugs...the data does not transfer which is why capre was hoping to use the strength data but that hope is gone now.

Valentin

StockTwits For Android 

 what exact data of the reduce it trial are you claiming acst will be able to use as their data? I'm gonna go with 0. Acst cannot use data from another trial for their p3. Capre and vascepa are 2 different drugs...the data does not transfer which is why capre was hoping to use the strength data but that hope is gone now.

Global X Dow 30 Covered Call ETF

Matt Jones

@robinandthe7hoods You really don&#39;t understand why a placebo is used do you?? The placebo was inert that&#39;s why the effect was only witnessed at 5 out of 54 sites.  You cant claim a  42% reduction for CAPre if those that were not taking it had a 30% improvement. Hence the need for an investigation because if they can&#39;t show  that the placebo group were either not given a placebo or took something other than the placebo then the result as it stands is correct

 You really don't understand why a placebo is used do you?? The placebo was inert that's why the effect was only witnessed at 5 out of 54 sites.  You cant claim a  42% reduction for CAPre if those that were not taking it had a 30% improvement. Hence the need for an investigation because if they can't show  that the placebo group were either not given a placebo or took something other than the placebo then the result as it stands is correct